CTOs on the Move


 
Ambys Medicines is a biotechnology company focused on discovering and developing regenerative and restorative therapies for people with advanced liver disease. Founded by world-renowned experts in liver disease and regenerative medicine, Ambys is pioneering the application of novel modalities including cell and gene therapy, and gain-of-function drug therapy, to meet the urgent need for treatments that have the potential to restore liver function and prevent the progression to liver failure across multiple liver diseases that are untreatable or poorly treated today. Ambys was launched in 2018 by Third Rock Ventures and Takeda Pharmaceuticals with $140M in starting capital and is ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.ambys.com
  • 131 Oyster Point Boulevard Suite 200
    South San Francisco, CA USA 94080
  • Phone: 650.481.7662

Executives

Name Title Contact Details
Alan Smith
Chief Technology Officer Profile

Funding

Ambys raised $60M on 08/08/2018
Ambys raised $80M on 08/08/2018

Similar Companies

89bio

We are a clinical-stage biopharmaceutical company focused on changing the lives of patients living with nonalcoholic steatohepatitis (NASH) and other liver and metabolic disorders. Our teams in the US and Israel are developing highly differentiated medicines that address unmet medical needs based on robust research. Our lead product candidate, BIO89-100, is a novel long-acting glycopegylated fibroblast growth factor 21 (FGF21) analogue.

Precision IBD

Precision IBD, Inc. is a biopharmaceutical company focused on the discovery an development of a broad portfolio of precision therapeutics and companion diagnostics for inflammatory bowel disease.

Ensoma

At Ensoma, we believe every person, no matter where they are in the world, should have access to innovative technologies that are changing the way we treat disease.

Zija International

Zija International is a Lindon, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Celgene

Celgene Corporation is an integrated global pharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. Our talent, scientific knowledge and research capabilities help us to deliver access to innovative, disease-altering therapies to those who need them most. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies. Celgene is headquartered in Summit, New Jersey, and employs more than 7,000 people located in more than 60 countries.